Premium
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM ‐003 trial for pomalidomide plus low‐dose dexamethasone
Author(s) -
Morgan Gareth,
Palumbo Antonio,
Dhanasiri Sujith,
Lee Dawn,
Weisel Katja,
Facon Thierry,
Delforge Michel,
Oriol Albert,
Zaki Mohamed,
Yu Xin,
Sternas Lars,
Jacques Christian,
Akehurst Ron,
Offner Fritz,
Dimopoulos Meletios A.
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13227
Subject(s) - pomalidomide , medicine , lenalidomide , dexamethasone , multiple myeloma , oncology
Summary In the phase III MM ‐003 trial, pomalidomide plus low‐dose dexamethasone ( POM +Lo DEX ) improved overall survival ( OS ) versus high‐dose dexamethasone (Hi DEX ) in 455 patients with relapsed and refractory multiple myeloma ( RRMM ) after treatment with bortezomib and lenalidomide. Here, a two‐stage Weibull method was used to adjust for the crossover of patients in the Hi DEX arm to pomalidomide‐based therapy. The adjusted difference in median OS between patients in the POM +Lo DEX and Hi DEX arms was 7·0 months (12·7 vs. 5·7 months, respectively). These findings provide important evidence for understanding the clinical efficacy of pomalidomide on OS benefits seen in RRMM patients.